Monday, 31 August 2015

Fingolimod in the real world

Totaro R, Di Carmine C, Costantino G, Fantozzi R, Bellantonio P, Fuiani A, Mundi C, Ruggieri S, Marini C, Carolei A. Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.
Mult Scler Int. 2015;2015:763418. doi: 10.1155/2015/763418.

Objective. The aim of this prospective observational multicenter postmarketing study was to evaluate fingolimod efficacy in a real world clinical setting. Methods. One hundred forty-two subjects with relapsing-remitting multiple sclerosis (RRMS) were enrolled in three multiple sclerosis centers throughout Central and Southern Italy between January 2011 and September 2013. After enrollment, regular visits and EDSS assessment were scheduled every 3 months, and MRI scan was obtained every 12 months. Patients were followed up from 1 to 33 months (mean 14.95 ± 9.15 months). The main efficacy endpoints included the proportion of patients free from clinical relapses, from disability progression, from magnetic resonance imaging activity, and from any disease activity. Results. Out of 142 patients enrolled in the study, 88.1% were free from clinical relapse and 69.0% were free from disability progression; 68.5% of patients remained free from new or newly enlarging T2 lesions and 81.7% of patients were free from gadolinium enhancing lesions. Overall the proportion of patients free from any disease activity was 41.9%. Conclusions. Our data in a real world cohort are consistent with previous findings that yield convincing evidence for the efficacy of fingolimod in patients with RRMS.

        Fingo in the real world gets it up their with the big boys

1 comment:

  1. Hmmm... mean follow-up time about a year. Let's give it 7 years and see how it does if your want a good comparison :-).
    I am coming off fingo, not because it doesn't work ( it does, I cannot complain), but because my neurologist can no longer accept low lymphocytes. ( I am now on 5 tablets a week and still grade 3 lymphopenia). Bad luck.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.